Daily Newsletter

17 August 2023

Daily Newsletter

17 August 2023

Smith+Nephew introduces OR3O system for hip arthroplasty

The system provides cross-compatibility with the R3 Acetabular System.

RanjithKumar Dharma August 17 2023

Smith+Nephew has introduced its OR3O Dual Mobility System in India for primary and revision hip arthroplasty applications.

Unlike traditional solutions, dual mobility implants feature a smaller diameter femoral head that securely engages with a larger polyethylene insert.

This enhances stability, lowers the chance of dislocation and provides a better range of motion.

While many hip implants use Cobalt Chrome liners and ceramic head balls, OR3O integrates Smith+Nephew's advanced bearing surface, OXINIUM diffusion hardened (DH), for its liner and OXINIUM on XLPE for the femoral head and polyethylene inserts.

This removes the modular CoCr liner or CoCr head ball from the structure, decreasing the potential for wear and corrosion issues linked to the alloy.

OXINIUM DH represents a distinct version of Smith+Nephew's OXINIUM Technology platform. It enhances hardening depth through the deployment of an additive manufacturing method.

The OR3O system also provides cross-compatibility with the R3 Acetabular System.

Smith+Nephew South Asia managing director Joaquin Lasso said: “Smith+Nephew's OR3O Dual Mobility System is a groundbreaking introduction for India that offers technology not available in other systems.

“Over a dozen peer-reviewed publications have now cited or expressed concerns over corrosion or elevated ions in CoCr modular dual mobility liners.

“The reduced corrosion of our OXINIUM and OXINIUM DH bearing surfaces sets OR3O apart from the competition.”

The company, which has operations in over 100 countries, generated annual sales of $5.2bn in 2022.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close